Stock EVT EVOTEC
Add to a list
To use this feature you must be a member
Log inSign up

Financials Evotec LIQUIDNET SYSTEMS

Equities

EVT

DE0005664809

Biotechnology & Medical Research

Real-time Estimate Tradegate
Other stock markets
 07:18:15 07/05/2024 BST 		5-day change 1st Jan Change
9.63 EUR -25.92% Intraday chart for Evotec 0.00% 0.00%
05-06 EVOTEC : Warburg Research reiterates its Buy rating ZD
05-03 EVOTEC : RBC reiterates its Buy rating ZD

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 3,473 4,950 7,444 2,696 3,765 1,703 - -
Enterprise Value (EV) 1 3,614 4,949 7,099 2,485 3,765 1,972 1,845 1,864
P/E ratio 92.2 x 757 x 32.7 x -15.4 x -45.3 x -57.9 x 30.4 x 23.4 x
Yield - - - - - - - -
Capitalization / Revenue 7.78 x 9.88 x 12 x 3.59 x 4.82 x 1.95 x 1.64 x 1.47 x
EV / Revenue 8.1 x 9.88 x 11.5 x 3.31 x 4.82 x 2.26 x 1.78 x 1.6 x
EV / EBITDA 29.3 x 46.4 x 66.2 x 24.4 x 56.7 x 20.1 x 8.43 x 6.95 x
EV / FCF 332 x -91.1 x 2,155 x 114 x - -9.26 x 27.5 x 17.4 x
FCF Yield 0.3% -1.1% 0.05% 0.88% - -10.8% 3.63% 5.74%
Price to Book 7.25 x 6.86 x 5.44 x 2.27 x - 1.58 x 1.51 x 1.48 x
Nbr of stocks (in thousands) 150,653 163,476 175,162 176,703 176,936 177,290 - -
Reference price 2 23.05 30.28 42.50 15.26 21.28 9.605 9.605 9.605
Announcement Date 26/03/20 25/03/21 12/04/22 12/05/23 24/04/24 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 446.4 500.9 618 751.4 781.4 874.1 1,037 1,162
EBITDA 1 123.1 106.6 107.3 101.7 66.35 98.02 218.9 268.2
EBIT 1 62.59 48.52 41 20.85 -26.63 -14.75 68.89 109
Operating Margin 14.02% 9.69% 6.63% 2.77% -3.41% -1.69% 6.64% 9.38%
Earnings before Tax (EBT) 1 56.56 25.81 237 -154 -80.59 -58.8 22.8 118.3
Net income 1 38.07 6.252 215.5 -175.7 -83.91 -29.9 33.99 80.05
Net margin 8.53% 1.25% 34.87% -23.38% -10.74% -3.42% 3.28% 6.89%
EPS 2 0.2500 0.0400 1.300 -0.9900 -0.4700 -0.1660 0.3154 0.4106
Free Cash Flow 1 10.89 -54.35 3.294 21.75 - -213 67 107
FCF margin 2.44% -10.85% 0.53% 2.89% - -24.37% 6.46% 9.21%
FCF Conversion (EBITDA) 8.85% - 3.07% 21.4% - - 30.61% 39.9%
FCF Conversion (Net income) 28.61% - 1.53% - - - 197.13% 133.67%
Dividend per Share 2 - - - - - - - -
Announcement Date 26/03/20 25/03/21 12/04/22 12/05/23 24/04/24 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2020 S1 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 S1 2022 Q3 2022 Q4 2023 Q2 2023 S1 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 231 159.7 187.1 164.7 172.2 336.9 173.9 240.7 170.3 383.8 196.3 250.1 208.1 204.8 218 233.7
EBITDA 47.27 - 37.21 18.9 14.7 33.64 10.96 57.05 - 26.1 24.11 16.14 - - - -
EBIT 1 18.92 - 14.94 0.463 -3.77 -3.307 -13.53 37.69 -36.29 - -12.19 -7.687 -8.57 -9.711 -5.675 -0.8139
Operating Margin 8.19% - 7.99% 0.28% -2.19% -0.98% -7.78% 15.66% -21.31% - -6.21% -3.07% -4.12% -4.74% -2.6% -0.35%
Earnings before Tax (EBT) 1 - - -17.84 - -24.34 - -43.36 -17.52 -20.44 - -29.92 -24.02 -10.96 -12.18 -8.312 -0.662
Net income 1 - - -31.48 -73.24 -27.94 -101.2 -47.28 -27.2 -14.93 -28.83 -38.96 -16.13 -22.88 -23.37 -20.88 -15.36
Net margin - - -16.83% -44.48% -16.22% -30.03% -27.19% -11.3% -8.77% -7.51% -19.85% -6.45% -11% -11.41% -9.58% -6.58%
EPS - - -0.2000 -0.4100 -0.1600 -0.5700 -0.2700 -0.1500 -0.0800 - -0.2200 -0.0900 - - - -
Dividend per Share - - - - - - - - - - - - - - - -
Announcement Date 12/08/20 12/11/21 12/04/22 11/05/22 11/08/22 11/08/22 09/11/22 12/05/23 29/08/23 29/08/23 08/11/23 24/04/24 - - - -
1EUR in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 141 - - - - 269 142 162
Net Cash position 1 - 0.67 345 212 - - - -
Leverage (Debt/EBITDA) 1.149 x - - - - 2.744 x 0.6476 x 0.6023 x
Free Cash Flow 1 10.9 -54.4 3.29 21.8 - -213 67 107
ROE (net income / shareholders' equity) 8.45% 1.04% 20.5% -13.7% - 2.6% 4.94% 5.47%
ROA (Net income/ Total Assets) 3.89% 0.47% 11.7% -7.82% - -0.48% 1.16% 2.06%
Assets 1 978.7 1,322 1,849 2,246 - 6,166 2,929 3,891
Book Value Per Share 2 3.180 4.420 7.810 6.720 - 6.090 6.360 6.490
Cash Flow per Share 2 0.2800 0.2900 0.7300 1.150 - 0.1900 0.7600 0.9400
Capex 1 31.3 99.1 119 181 - 162 119 129
Capex / Sales 7.02% 19.78% 19.25% 24.13% - 18.58% 11.44% 11.12%
Announcement Date 26/03/20 25/03/21 12/04/22 12/05/23 24/04/24 - - -
1EUR in Million2EUR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Evotec

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
9.605 EUR
Average target price
21.99 EUR
Spread / Average Target
+128.94%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
MODERNA, INC. Stock Moderna, Inc.
+22.81% 46.81B
LONZA GROUP AG Stock Lonza Group AG
+46.56% 41.29B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-1.88% 41.37B
CELLTRION, INC. Stock Celltrion, Inc.
-6.20% 28.87B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+11.33% 26.06B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-21.00% 19.13B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-1.43% 11.96B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+30.73% 12.39B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-0.48% 12.08B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. EVT Stock
  4. EVT Stock
  5. Financials Evotec